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Since its introduction into clinical practice in 1967, selective variceal decompression by means of a distal
splenorenal shunt (DSRS) has become one of the more commonly performed portal-systemic shunting
procedures in the treatment of variceal hemorrhage throughout the world. In addition to selective
decompression of gastroesophageal varices, the DSRS provides the advantages of preservation of portal
perfusion of the liver and maintenance of intestinal venous hypertension. Many large, uncontrolled
series and the majority of controlled randomized studies have demonstrated a lower incidence of
encephalopathy after the DSRS than after nonselective shunt procedures. A secondary advantage of the
DSRS is that the hepatic hilum is avoided, thus making subsequent liver transplantation a less
formidable procedure. None of the studies have shown an advantage to this shunt with respect to long-
term survival in patients with alcoholic cirrhosis. However, some of the large, uncontrolled series have
shown that survival is significantly improved in patients with non-alcoholic cirrhosis compared to
nonselective shunt procedures in the same population. Controlled trials comparing the DSRS to
endoscopic sclerotherapy have shown that chronic endoscopic variceal sclerosis is an appropriate initial
therapy for most patients as long as shunt surgery is readily available if sclerotherapy fails.
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RATIONALE AND HISTORY/BACKGROUND
Although surgical portal flow diversion was initially achieved by Nicolai Eck in
1877, Pavlov was the first to describe the physiologic consequences of the portapri-
val state 1. In 1893, Pavlov’s careful observations of dogs with portacaval shunts
resulted in the description of the syndrome of "meat intoxication" or portasystemic
encephalopathy. In addition, autopsy studies disclosed that animals that developed
portasystemic encephalopathy had patent portacaval shunts and atrophic livers,
whereas dogs with thrombosed or stenosed shunts had normal livers and hepatope-
tal portal collaterals. Pavlov concluded from these experiments that portal blood
flow was essential for maintenance of liver function and structure and that complete
portal diversion caused psychoneurologic dysfunction secondary to hepatic func-
tional deterioration from reduced nutrient liver blood flow and to intestinally
absorbed cerebral toxins bypassing hepatic detoxification.
Because there was no effective therapy for treatment of life-threatening variceal
bleeding, Whipple and his associates introduced portacaval and conventional
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splenorenal shunts into clinical practice in 19452’3. Their initial reports as well as
several subsequent non-randomized studies showed that total portal decompression
was an effective treatment for variceal hemorrhage. It was not until the 1960s,
however, that the portacaval shunt was evaluated in randomized controlled trials4.
Several such studies of both prophylactic and therapeutic portacaval shunts versus
conventional medical treatment showed similar results" effective control of variceal
hemorrhage, no survival advantage for patients with portacaval shunts, and
accelerated hepatic failure and severe encephalopathy in patients with shunts.
Although the portacaval shunt prevented hemorrhage, it did not prolong survival.
It simply changed the mode of death from hemorrhage to hepatic failure.
These disappointing clinical results as well as animal studies, which demonstrated
that portal blood contains hepatotrophic factors that are essential for liver mainten-
ance and regeneration, were the major stimuli to search for a shunt which could
control variceal hemorrhage but also maintain portal perfusion of the liver. The
concept of selective variceal decompression by means of a distal splenorenal shunt
(DSRS) was described in 1967 by Warren, Zeppa, and Fomon5. The operation was
designed to provide selective transsplenic decompression of gastroesophageal
varices, while preserving portal perfusion of the liver and maintaining mesenteric
venous hypertension. They demonstrated that these objectives could be achieved
by separating the splanchnic venous system into two compartments, a high pressure
portomesenteric compartment and a low pressure gastrosplenic compartment,
which is decompressed via a DSRS. These two components of the portal venous
system were separated by interrupting the veins which connected them, including
right and left gastric veins and the right gastroepiploic vein.
In 1968, Inokuchi described another selective shunt, the left gastric vena caval
shunt6. This procedure achieves selective decompression of esophagogastric varices
by anastomosis of the coronary vein to the inferior vena cava or interposition of a
graft between these two veins. Even though this selective shunt was introduced at
about the same time as the DSRS, experience with it has been almost entirely
confined to Japan.
DISTAL SPLENORENAL SHUNT
Indications and Contraindications
An absolute contraindication to the DSRS is incompatible anatomy. In patients
with prior splenectomy or splenic vein thrombosis, the DSRS is technically not
feasible. In addition, we generally select another therapy for individuals whose
splenic vein is less than 8 mm in diameter, because of the high incidence of shunt
thrombosis in such patients.
Preoperative ascites has often been cited as a contraindication to the DSRS,
because this procedure tends to aggravate rather than resolve ascites. However,
most surgeons believe that transient preoperative ascites is not a contraindication
to the DSRS. Ascites often develops after resuscitation from a variceal hemorr-
hage, but conservative medical treatment usually results in disappearance or
stabilization of the ascites. The DSRS can generally be safely performed in such
patients. Successful DSRS has also been reported in patients with massive ascites7.
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Medical treatment resolves ascites in approximately 95% of patients after the
DSRS. Peritoneovenous shunts should be reserved only for patients whose ascites
is truly refractory to medical treatment. In our experience of 124 patients, the
incidence of ascites severe enough to prolong hospitalization after the DSRS was
19% and only 2 patients (1.6%) required peritoneovenous shunting. Since severe
postoperative ascites was a significant contributing factor to 10 postoperative
deaths in our series, we prefer a side-to-side portal-systemic shunt (interposition or
portacaval) rather than a DSRS for patients with variceal hemorrhage and medi-
cally intractable ascites.
In most centers, emergency surgery has played a decreasing role in the manage-
ment of acute variceal hemorrhage as endoscopic sclerotherap.y has become
available. However, there remains an important role for emergency portasystemic
shunting in patients who are refractory to nonoperative therapies9’1’1. The most
frequently used emergency shunts are the end-to-side portacaval shunt and the
interposition mesocaval shunt. Whether the DSRS should be used in the emerg-
ency setting is controversial. Many believe that the technical complexity of the
procedure and the short-term incomplete variceal decompression provided by the
DSRS are not suited to the emergency situation. However, when surgery is urgent
rather than emergent (e.g. bleeding temporarily controlled by balloon tamponade),
we believe that a DSRS is an effective and reasonable alternative. If the surgeon is
experienced in performing this procedure, the operative mortality rate appears to
be similar to other emergency operations. The experience with emergency DSRS
has shown effective control of variceal bleeding in 95% of patients with mortality
being related to the status of the underlying liver disease12. In a collected group of
173 patients undergoing emergency DSRS, the operative mortality rates ranged
from 13 to 50% with an overall rate of 29% 7’10’12"’19. When possible, visceral
angiography should precede surgery in patients undergoing the DSRS. In the
emergency setting, the alternative of a distal splenocaval shunt should be con-
sidered, particularly when the left renal vein is abnormal or small’2. An advan-
tage of the distal splenocaval shunt is that it eliminates the possibility of postopera-
22 tive renal venous hypertension
In most Western centers, visceral angiography is done prior to the DSRS and this
procedure is reserved for patients with hepatopetal portal flow. However, when
medically intractable ascites is not a complicating factor, patients with absent
hepatic portal perfusion may be reasonable candidates for this operation. We have
found that portal flow to the liver is restored in some of these patients23, and even in
the absence of hepatic portal perfusion, the maintenance of intestinal venous
hypertension after the DSRS may be beneficial, because it inhibits intestinal
24 absorption of substances that may cause portasystemic encephalopathy
Due to the limited resources in developing countries, it is impossible to perform
routine angiography for every patient who undergoes the DSRS. In a collected
group of 302 patients undergoing the DSRS, only 31 (10%) received preoperative
angiographic studies. The results of DSRS in these patients were satisfactory with
an overall operative mortality of 6% Thus, though desirable, preoperative
angiography is not mandatory prior to a DSRS.
Most Chinese and Japanese surgeons advocate prophylactic shunts for patients
with high risk varices which have not previously bled. Prophylactic shunts account
for 25 to 39% of shunt operations in several Eastern series7’. Of 302 DSRS
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receiving a left gastric-vena caval shunt, approximately 25% were prophylactic
operations25. In a Japanese series of 78 patients,
19 29 (37%) underwent a prophylac-
tic DSRS, with an operative mortality of 3.4%; the 5-, 10- and 15-year survival
rates all exceeded 85%. Despite these good results, no controlled trial has yet
justified any shunt procedure for patients with varices which have not previously
bled.
An additional reason to consider the DSRS is that dissection in the porta hepatis
is avoided, thereby making the technical aspects of subsequent liver transplantation
less difficult than if a portacaval shunt had been done26. Successful liver transplan-
tation in patients with a previous DSRS has been reported26-29. Recently,
Mazzaferro et al. 28 reported their experience of liver transplantation in 58 patients
who had previous portasystemic shunts including 18 who had received the DSRS.
They demonstrated that mortality after transplantation was less if the previous
shunt procedure did not require liver hilum dissection. Complete portal vein
thrombosis develops in 5% to 10% of patients after the DSRS. However, this
complication does not eliminate the option of liver transplantation, which can be
accomplished by interposing a vein graft between the donor portal vein and the
recipient superior mesenteric vein28.
Maintenance of Hepatic Portal Perfusion after the DSRS
In addition to selective decompression of esophagogastric varices, two objectives of
the DSRS are preservation of portal perfusion of the liver and maintenance of
portal venous hypertension. Clinical results are best when both of these objectives
are attained3’31. A major controversy regarding the DSRS is for how long and to
w.hat degree these variables are maintained postoperatively. Approximately 90%
of patients with the DSRS have continuing portal flow in the early postoperative
interval32-34. Loss of portal flow to the liver at this early point after the operation is
most frequently secondary to portal vein thrombosis. Portal vein thrombosis as an
early postoperative complication of the DSRS was first recognized in 197835. Since
then multiple reports have appeared with the incidence of total and partial portal
vein thrombosis ranging from 5 to 19% and from 3 to 25%, respectively. The
frequencies of total (10.5%) and partial portal vein thrombosis (17.7%) in our
recent review of 124 patients with DSRS
36 are similar to those previously reported
in the literature33’37. However, even when the portal vein is patent, the magnitude
of portal flow is significantly decreased because of the loss of splenic venous flow.
Analysis of 10 patients in our institution by duplex ultrasonography before and
after the DSRS revealed diminution of portal flow by more than 50% in the early
postoperative period38.
A key factor in determining long-term maintenance of portal flow to the liver
after the DSRS is etiology of liver disease. Patients with non-alcoholic cirrhosis and
non-cirrhotic portal hypertension are more likely than patients with alcoholic
cirrhosis to maintain hepatopetal portal flow in the late postoperative period39.
Long-term follow-up of patients in the Emory randomized trial of DSRS versus
nonselective shunt has shown that continuing portal flow to the liver was main-
tained for as long as 10 years in some patients with non-alcoholic cirrhosis4. In one
series, 80% of non-alcoholic cirrhotics and only 25% of alcoholic cirrhotics had
evidence of continuing portal perfusion of the liver at the one year evaluation39.
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alcoholic and non-alcoholic cirrhosis is not clear. The group of patients most likely
to maintain continuing hepatic portal perfusion after the DSRS are those with
portal hypertension secondary to portal vein thrombosis
41 and to schistosomiasis,
42
but with normal liver architecture and function. Portal flow in patients with portal
vein thrombosis is restored through hepatopetal collaterals, and since hepatic
vascular resistance is normal, hepatic portal perfusion can usually be maintained
indefinitely after the DSRS.
Other than the cause of portal hypertension, the extent to which the superior
mesenteric venous part of the portal venous system is separated from the decom-
pressed gastrosplenic component is another important factor in determining portal
flow preservation. When the devascularization component of the operation is
omitted, loss of portal flow through the coronary vein to the shunt is quite rapid43.
However, even when portal-azygous disconnection is performed appropriately,
portal flow is lost at a more rapid rate than in unshunted patients4’5.
Recently both Warren and Inokuchi
"/ have shown that a major route for
collateralization after the DSRS is through the pancreas. Since the splenic vein is in
continuity with the pancreatic venous circulation via multiple small pancreatic
branches, hepatic portal perfusion may gradually be lost through a "pancreatic
siphon’’48. To avoid the "pancreatic siphon" effect, both Warren
49 and Inokuchi47
have suggested total disconnection of the splenic vein from the pancreas up to its
bifurication at the splenic hilus, thereby separating the shunt from the pancreatic
venous drainage. This extension of the DSRS operation is termed spleno-
pancreatic disconnection. More extensive separation of the portomesenteric com-
ponent of the splanchnic venous system from the decompressed gastrosplenic
circuit is achieved with splenopancreatic disconnection1’5-53. In an initial evalu-
ation of alcoholic cirrhotics at Emory, Warren and associates showed that portal
perfusion of the liver at one year was preserved in a high percentage of patients
who underwent splenopancreatic disconnection in addition to the DSRS, whereas
few alcoholic cirrhotics had continuing hepatopetal flow to the liver when the
standard DSRS was done. More recently, Henderson and co-workers1 have
reviewed the hemodynamic status of 78 patients undergoing DSRS and splenopan-
creatic disconnection. In their uncontrolled study, they found that hepatic portal
perfusion was maintained in 84% of alcoholic and 90% of non-alcoholic patients at
four years after surgery. After splenopancreatic disconnection, survival and late
postoperative hepatic function were similar in alcoholic and non-alcoholic cirrho-
tics. Disadvantages of the procedure were longer operations, greater blood loss,
and an increased incidence of recurrent hemorrhage from gastric varices49.
Whether this variation on the DSRS operation will improve long-term clinical
results has yet to be determined11. Since splenopancreatic disconnection is a more
technically demanding operation than the originally described DSRS, we believe
that it should not be recommended for routine application until its clinical benefits
have been demonstrated in a randomized controlled trial. If performed by inexper-
ienced surgeons, the splenic vein may be damaged, thus eliminating the option of
selective variceal decompression.
Several studies have shown that there is gradual attrition of portal venous
perfusion of the liver over subsequent months and years as collaterals from the high
pressure portomesenteric venous compartment to the low pressure gastrosplenic
system develop4-6. Data from Emory’s study showed that 98% of patients
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alcoholic patients developed the same collateral pathways with pancreatic collater-
als being most prominent in leading to gradual loss of portal flow in alcoholic
patients39’48. However, despite the development of portal systemic collaterals,
hepatic portal perfusion was preserved in 68 to 80% of patients after the DSRS48’54.
Even when portal perfusion of the liver is markedly diminished or lost after the
DSRS, maintenance of mesenteric venous hypertension may be beneficial by
inhibiting intestinal absorption of nitrogenous substances that have been implicated
in the pathogenesis of encephalopathy. We have shown that intestinal absorption of
D-xylose is minimally changed one year after the DSRS, but significantly increased
after nonselective shunts24. In addition, the higher postoperative blood ammonia
concentrations in nonselective shunt patients correlated with the changes in
D-xylose absorption induced by total portal decompression. Thus, even when
portal flow is absent after the DSRS, residual portal hypertension may protect
against the development of postoperative encephalopathy.
Non-Randomized Experience with the DSRS
In 1984, Henderson et al. reviewed the world-wide non-randomized experience
with the DSRS which had been accumulated over the prior 17 years8. The mean
rates for operative mortality, shunt patency, and variceal rebleeding were 9%,
90%, and 7%, respectively. The reported incidences of encephalopathy ranged
from 0 to 18%.
Since Henderson’s report, the DSRS has become the shunt of choice for variceal
hemorrhage in many centers. Series consisting of more than 2,700 patients
undergoing the DSRS have been published in the English literature since 1984
(Table 1)7’10’13-19’42’50’52’53’57-64. This widespread application of the DSRS by surgical
groups in North and Central America, Europe, Africa, and Asia is testimony to the
successful adoption of this procedure by a large number of surgeons. In contrast to
the randomized trials of the DSRS, which contain mainly patients with alcoholic
cirrhosis, 70% of patients in these uncontrolled studies had non-alcoholic cirrhosis
or noncirrhotic portal hypertension. In these series, 44% of patients were classified
as Child’s A, 42% as Child’s B, 14% as Child’s C. The results of the non-
randomized studies were fairly consistent from series to series and identical with
Henderson’s previous report. This extensive uncontrolled experience with the
DSRS cannot be meaningfully compared to most published series of nonselective
shunts because the patient populations are so dissimilar. However, where compari-
sons can be made, the DSRS appears to be nearly as effective in preventing
recurrent variceal hemorrhage and to be followed by a lower frequency of
encephalopathy than nonselective shunts.
Between 1984 and 1990, 1,111 DSRS’s were reported from 13 centers in Western
countries1’13’15-17’36’53’57-6’63’64. These series ranged from 40 to 177 patients; the cause
of portal hypertension was alcoholic cirrhosis in 50% of the patients. Since 1984,
the Eastern experience (mainly Chinese and Japanese), encompasses large collect-
ed series with a combined total of 735 patients7’19’5’52’61’62. Prophylactic shunts
accounted for 25 to 39% of shunt operations in several Eastern series. Over 90% of
the patients had either posthepatitic or cryptogenic cirrhosis. The Western exper-
ience of the past seven years showed an overall operative mortality rate of 12%.
This mortality rate, although mainly for elective operations, included an increasingSELECTIVE VARICEAL DECOMPRESSION 7
Table 1 World-wide non-randomized experience with DSRS
1967-1983 1984-1990 Total
Number of reports 20 24 44
Number of patients > 1,000 >2,700 >3,700
Etiology: alcoholic cirrhosis (%) 60 20 30
nonalcoholic disease (%) 40 80 70
Child’s Class: A (%) 46 42 44
B (%) 40 43 42
C(%) 14 15 14
Operative mortality (%) 9 8 8
Shunt patency (%) 90 94 >90
Variceal rebleeding (%) 7 6 <7
Encepalopathy (%) 10 7 <10
5-year survival (%) 50-60 50-70 50-70
Schistosomiasis patients not included
Reports with patient number less than 40 not included
number of emergency procedures in at least six reports1’12-6. Of 856 cases, 119
patients (14%) underwent an emergency operation. The operative mortality rates
from the Eastern experience ranged from 1.8 to 15.8% with an overall rate of
5.7%. Decreasing operative mortality with increasing operative experience was
reported in several studies1’5’63. The recurrent bleeding and shunt occlusion rates
averaged approximately 7% in both Western and Eastern experiences. The overall
incidence of all types of encephalopathy was 11.7% in Western reports and 6.5% in
Eastern series. In most cases, encephalopathy was mild and could be reversed by
conventional treatment. In most of these investigations, five-year survival rates
were between 50% and 70%.
The two largest uncontrolled series from Western countries have demonstrated a
survival advantage for patients with non-alcoholic cirrhosis compared with those
with alcoholic cirrhosis32’65. However, several investigators have reported no
significant difference in survival rates for alcoholic and non-alcoholic cirrhotics
undergoing the DSRS 10’11’34’58’63’66. It is not clear why the prognosis of non-alcoholic
cirrhotics has varied among these different centers, but it probably relates to
different types of non-alcoholic cirrhosis and to varying levels of hepatic functional
reserve.
The most common cause of portal hypertension and esophagogastric variceal
hemorrhage world-wide is hepatic schistosomiasis. Since the mid-1970s, groups in
both the Middle East and South America have applied the DSRS to this population
because of unacceptably high rates of encephalopathy after nonselective shunts and
frequent recurrent bleeding in some series after devascularization operations. Since
1984, 887 schistosomiasis patients who have received a DSRS, have been
reported13’18’42’67’68. The overall encephalopathy rate in these series is less than 2%,
which is considerably less than the incidence of this complication after the DSRS in
cirrhotic patients4. The five-year survival rate reported by Egyptian investigators in
schistosomiasis patients after the DSRS was 91.5%, which was higher than survival
figures in cirrhotic patients (75.6%) and mixed groups (65.2%) treated concomi-
tantly in the same center67. Undoubtedly, these favorable results were obtained
because liver function in the majority of patients was normal. It can be concluded8 G. JIN AND L. F. RIKKERS
from these series that the DSRS is an effective and safe procedure in the treatment
of patients with schistosomiasis and variceal hemorrhage. Encephalopathy and
hepatic failure after the DSRS are less frequent in schistosomal patients than in
patients with alcoholic or non-alcoholic cirrhosis.
Controlled Comparisons of the DSRS with Non-selective Shunts
A total of seven randomized trials have compared the DSRS to a variety of
nonselective shunts4’69-74 (Table 2). In six of these studies, the patient populations
of both groups were comprised of predominantly patients with alcoholic cirrhosis
and the seventh trial contrasted the DSRS to a nonselective shunt and a non-
shunting procedure in schistosomiasis patients. To date, no investigation has
compared different shunt procedures in patients with non-alcoholic cirrhosis. A
consistent finding in all of the studies is that survival was not improved after the
DSRS.
Four of the seven trials4’69’71’73 have shown a significantly lower frequency of
postshunt encephalopathy in the DSRS patients; however, the other three trials
have demonstrated no significant difference between selective and nonselective
shunts in the incidence of this complication. In contrast to survival, encephalopathy
is a subjective endpoint which was assessed with a variety of methods in the
different trials. One of the more objective assessments quantified encephalopathy
by the number of postoperative hospital admissions required for the treatment of
this complication. This trial showed significantly fewer days of hospitalization for
encephalopathy in the DSRS than in the portacaval shunt group71. These discrepan-
cies in the frequencies of post-DSRS encephalopathy are probably due to differ-
ences in the patient populations studied, the methods used in assessing neuropsy-
chological function and surgical technique. It is possible that technical variations
resulting in less complete portal-azygous disconnection in the DSRS groups of two
trials contributed to the higher incidence of post-DSRS encephalopathy observed
in these studies72’74.
Another important endpoint in comparing treatment for variceal hemorrhage is
the effectiveness with which recurrent bleeding is prevented. Bleeding control was
similar after selective and nonselective shunts in six of these studies4’69-7’73’74
Likewise, selective and nonselective shunt occlusion rates were similar in these six
trials. The Los Angeles study
72 showed a higher shunt failure rate after selective
variceal decompression. The 30% incidence of recurrent variceal hemorrhage after
the DSRS in that trial is the highest ever reported, suggesting a degree of surgeon
inexperience with this procedure, as the frequency of DSRS failure was less than
10% for the other six studies combined.
In summary, these prospective randomized trials have shown no significant
improvement in survival in alcoholic cirrhotic patients managed by the DSRS
compared to those undergoing a nonselective shunt procedure. Selective variceal
decompression provided a better quality of survival in four of the studies, even
though three of these investigations contained mostly patients with alcoholic
cirrhosis75. Prevention of recurrent variceal hemorrhage was equivalent for selec-
tive and nonselective shunts in six of the investigations. Although there are less
controlled data, superiority of the DSRS may be more evident in patients with non-
cirrhotic portal hypertension68’73 and in those with non-alcoholic cirrhosis32’65. A
single controlled trial in patients with schistosomiasis showed a lower frequency of10 G. JIN AND L. F. RIKKERS
encephalopathy after DSRS than following a conventional splenorenal shunt. The
morality rate was low after both procedures in this investigation.
Controlled Comparisons of the DSRS with Endoscopic Sclerotherapy
Four randomized controlled trials44’45’76’77 have compared the DSRS to chronic
sclerotherapy as definitive treatment for variceal hemorrhage in patients with
cirrhosis (Table 3). Three of the studies44’76’77 exclusively utilized the DSRS in the
surgical group while the fourth trial,
45 conducted in our institution, utilized both
selective (85%) and nonselective shunts (15%). All of the studies demonstrated
significantly lower recurrent hemorrhage rates after the DSRS. In the two North
American trials,44’45 sclerotherapy failure secondary to uncontrolled recurrent
variceal hemorrhage occurred in approximately one-third of patients. In the
Atlanta trial,
44 82% of sclerotherapy failures were salvaged by shunt surgery,
whereas only 20% of sclerotherapy failures were salvaged in the Omaha study45.
These contrasting salvage rates are most likely due to the different patient
populations of the two trials. The Omaha study contained a higher percentage of
patients with alcoholic cirrhosis, who lived in relatively remote geographic areas.
Many of these patients died from recurrent hemorrhage before they could be
transferred for shunt surgery. Sclerotherapy with surgical rescue in one-third of
patients resulted in significantly longer survival than initial DSRS in the Atlanta
trial. However, survival curves for sclerotherapy and shunt surgery were not
significantly different in the Omaha study45. The investigations by Teres and
co-workers in Spain and Spina and co-workers in Italy also found no significant
difference in survival after the DSRS and endoscopic sclerotherapy, despite the
higher rebleeding rate in the sclerotherapy group.
Three of these studies44’45’76 showed no significant difference in frequency of
encephalopathy after the DSRS and endoscopic sclerotherapy, while the fourth
investigation
77 demonstrated a higher encephalopathy rate after the DSRS (24%)
than after endoscopic variceal sclerosis (8%). This may have been due to the
modified surgical technique used, which did not include portal-azygous disconnec-
tion with the DSRS. These investigators concluded that endoscopic sclerotherapy is
a reasonable alternative to selective shunting for long-term management of variceal
hemorrhage, especially in patients who are prone to encephalopathy.
Two of these studies evaluated the effect of the DSRS and endoscopic sclerother-
apy on hepatic hemodynamics and quantitative liver function44’45. Significantly
more patients had continuing hepatic portal perfusion at the one-year assessment in
the sclerotherapy groups of both of these investigations. This difference in portal
flow between treatment groups resulted in significantly better hepatic functional
reserve in the sclerotherapy group of the Atlanta study but not in the Omaha trial.
Our conclusion from these four studies is that chronic sclerotherapy is an
acceptable, but not superior, alternative to the DSRS for management of patients
with variceal hemorrhage. Recurrent variceal hemorrhage is common after defini-
tive sclerotherapy and this treatment modality will fail in approximately one-third
of patients. Although sclerotherapy may be the preferred initial treatment for many
variceal bleeders, patients living in remote areas or those who are non-compliant
with respect to their sclerotherapy schedule should probably undergo an initial
shunt operation rather than receive chronic sclerotherapy.SELECTIVE VARICEAL DECOMPRESSION 11
Table 3 Controlled trials of endoscopic sclerotherapy versus DSRS
Rikkers
45 Warren44 Teres77 Spina
76
2-Year survival after DSRS (%) 65 59* 71 95
after EVS (%) 61 84* 68 90
Encephalopathy after DSRS (%) 16 16 24" 5
after EVS (%) 7 12 8* 10
Rebleeding after DSRS (%) 19" 3* 14" 5*
after EVS (%) 57* 53* 38* 35*
DSRS Distal splenorenal shunt; EVS Endoscopic variceal sclerotherapy
p<0.05
THE LEFT GASTRIC-VENA CAVAL SHUNT
The left gastric-vena caval shunt was proposed by Inokuchi in 19686. In 1990,
Inokuchi and associates
52 reported their experience with this operation in 258
patients with either cirrhosis or idiopathic portal hypertension. Approximately
25% of the operations were done prophylactically in patients who had never bled
from varices. Postoperative encephalopathy was infrequent, recurrent variceal
hemorrhage complicated the course of 8% of patients, and the shunt was patent in
88% of patients who underwent postoperative angiography. Although results with
this procedure in patients with non-alcoholic cirrhosis have been excellent, the left
gastric-vena caval shunt has not been compared to other therapies in a randomized,
controlled trial and no large series of patients with alcoholic cirrhosis undergoing
this procedure has been reported. This procedure has occasionally been used as an
alternative means of selective shunting in patients in whom prior splenectomy has
obviated a DSRS46. In many patients with portal hypertension, the coronary vein is
thin and friable, which adds to the technical difficulty of the procedure.
Furthermore, patients with alcoholic cirrhosis frequently have edematous, thick-
ened retroperitoneal tissue which makes this operation more difficult to accom-
plish. Most likely because of these factors, this selective shunt has not been widely
applied outside of Japan.
CONCLUSIONS
The available data from randomized trials and the world-wide non-randomized
experience have led us to the following conclusions regarding the current status of
the DSRS"
1. The DSRS has gained widespread acceptance for patients with variceal
hemorrhage with more than 2,700 cases being reported in the world literature
since 1984.
2. The DSRS is nearly as effective as nonselective shunts in preventing recurrent
hemorrhage.
3. The major contraindications to the DSRS are medically intractable ascites and
anatomic limitations (prior splenectomy or splenic vein less than 8mm in
diameter).12 G. JIN AND L. F. RIKKERS
4. When surgery is urgent rather than emergent, a DSRS is an effective and
reasonable alternative for many patients.
5. Hepatic portal perfusion after the DSRS can be maintained in the majority of
patients during the early postoperative interval. However, in many patients
(mainly alcoholic cirrhotics), portal flow gradually collateralizes to the shunt.
Porthl flow may be better preserved after splenopancreatic disconnection, but
no clinical benefits have yet been established for this technically difficult
extension of the DSRS.
6. Randomized trials of the DSRS versus nonselective shunts, which have
included mainly patients with alcoholic cirrhosis, have shown no advantage to
the DSRS with respect to long-term survival. Some large, nonrandomized
experiences, have demonstrated longer survival in non-alcoholic than in
alcoholic cirrhotics.
7. The majority of controlled trials and most nonrandomized comparisons have
demonstrated a lower frequency of encephalopathy after the DSRS than after
nonselective shunts. This difference is particularly striking in patients with
schistosomiasis.
8. Chronic sclerotherapy and the DSRS have provided similar results in most
controlled trials. In settings where sclerotherapy failure can be effectively
salvaged by shunt surgery, chronic sclerotherapy is the preferable initial
treatment. However, the DSRS may be the superior initial therapy for
individuals living in remote geographic areas and for those who are likely to be
noncompliant.
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